RGH-202 Capsules for Performance and Social Interaction Anxiety in Adults With Social Anxiety Disorder

This Phase 2a study is testing whether RGH-202, an investigational oral capsule from Gedeon Richter, is safe, well tolerated, and helps reduce performance and social interaction anxiety in adults with Social Anxiety Disorder. Participants are randomly assigned (1:1) to RGH-202 56.25 mg or a matching placebo for about 6 weeks, with weekly study visits. Effectiveness is measured with a public speaking challenge and the Liebowitz Social Anxiety Scale. Total participation is up to 12-13 weeks, including a screening period of up to 28 days and a follow-up visit 2 weeks after the last dose. About 156 adults will be randomized at approximately 12 sites in the United States.